Clinical Trial Update: Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating darbepoetin alfa in patients with poor-prognosis germ cell tumor treated with high-dose VIP chemotherapy (dysgerminoma) has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysgerminoma

Drugs mentioned

• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Dysgerminoma | Phase 2 | Status: COMPLETED